Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Pneumonia V: Nursing management and Prevention

Pneumonia V: Nursing management and Prevention

Nursing management of pneumonia involves promoting airway patency, facilitating rest and conserving energy, encouraging fluid intake, maintaining nutrition, and educating patients.
The nurse must practice strict medical asepsis and adhere to infection control guidelines to minimize healthcare-associated infections.
Enhance airway patency
Position the patient correctly to facilitate drainage of the affected lung segments. Manual or mechanical percussion and vibration can also be employed....

Pneumonia II: Pathophysiology

Pneumonia II: Pathophysiology

The pathophysiology of pneumonia involves the following steps:

Pneumonia I: Introduction

Pneumonia I: Introduction

Pneumonia is an acute respiratory infection that targets the lungs, specifically the alveoli. These tiny air sacs, essential for oxygen exchange, become engorged with pus and fluid, severely hindering breathing, decreasing oxygen absorption, and causing significant pain and discomfort during respiration.
Risk Factors
Various factors influence the likelihood of developing pneumonia. Age plays a crucial role, with infants, children under two, and individuals over 65 at increased risk due to their...

Pneumonia IV: Management

Pneumonia IV: Management

The treatment of pneumonia varies based on its severity and the causative pathogen. Here is a structured approach to managing pneumonia, integrating pharmaceutical and supportive care strategies.
Bacterial Pneumonia Treatment
For bacterial pneumonia, antibiotics serve as the cornerstone of therapy. Initial treatment often begins with empirical antibiotics, tailored to the anticipated causative organism and adjusted based on culture results. Key antibiotic choices include:

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Landscape of Prophylactic Strategies Against Human Parainfluenza Virus Type 3.

Reviews in medical virology·2025

Same author

Long COVID Symptom Management Through Self-Care and Nonprescription Treatment Options: A Narrative Review.

International journal of environmental research and public health·2025

Same author

Metavac-RSV mucosal bivalent vaccine candidate protects cotton rats against pneumoviruses and is produced using serum-free cell culture in bioreactor.

NPJ vaccines·2025

Same author

In Silico Analysis of Mechanisms of Maribavir-Induced Inhibition and Drug Resistance Mutations in pUL97 Kinase Structural Prediction with AlphaFold2.

Viruses·2025

Same author

Influenza A virus interferes with respiratory syncytial virus in mice and reconstituted human airway epithelium.

Microbiology spectrum·2025

Same author

A Novel In Vitro Primary Human Alveolar Model (AlveolAir™) for H1N1 and SARS-CoV-2 Infection and Antiviral Screening.

Microorganisms·2025

Search research articles

Related Experiment Video

Updated: Sep 18, 2025

Expression and Purification of Virus-like Particles for Vaccination

Expression and Purification of Virus-like Particles for Vaccination

Published on: June 2, 2016

Vaccine Development for Human Pneumoviruses.

Elhadji Birane Mboup¹, Marie-Ève Hamelin^1,2, Julia Dubois^2,3,4

¹Infectious and Immune Diseases Research Program, CHU de Québec-Université Laval Research Center, Québec, QC G1V 4G2, Canada.

|June 27, 2025

Summary

This summary is machine-generated.

Three respiratory syncytial virus (RSV) vaccines are now approved, offering new prevention methods. However, vaccines for human metapneumovirus (HMPV) are still needed, with combination vaccines showing future promise.

Keywords:

clinical trial human metapneumovirus (HMPV)lower respiratory tract infection (LRTI)pneumovirus respiratory syncytial virus (RSV)vaccine

More Related Videos

Experimental Human Pneumococcal Carriage

Experimental Human Pneumococcal Carriage

Published on: February 15, 2013

Following in Real Time the Impact of Pneumococcal Virulence Factors in an Acute Mouse Pneumonia Model Using Bioluminescent Bacteria

Following in Real Time the Impact of Pneumococcal Virulence Factors in an Acute Mouse Pneumonia Model Using Bioluminescent Bacteria

Published on: February 23, 2014

Related Experiment Videos

Last Updated: Sep 18, 2025

Expression and Purification of Virus-like Particles for Vaccination

Expression and Purification of Virus-like Particles for Vaccination

Published on: June 2, 2016

Experimental Human Pneumococcal Carriage

Experimental Human Pneumococcal Carriage

Published on: February 15, 2013

Following in Real Time the Impact of Pneumococcal Virulence Factors in an Acute Mouse Pneumonia Model Using Bioluminescent Bacteria

Following in Real Time the Impact of Pneumococcal Virulence Factors in an Acute Mouse Pneumonia Model Using Bioluminescent Bacteria

Published on: February 23, 2014

Area of Science:

Virology
Immunology
Vaccinology

Background:

Pneumoviruses, including respiratory syncytial virus (RSV) and human metapneumovirus (HMPV), cause significant global respiratory illness and mortality.
Young children, the elderly, and immunocompromised individuals are particularly vulnerable to severe outcomes.
Low- and middle-income countries bear a disproportionate burden of pneumovirus-related deaths.

Purpose of the Study:

To review clinical trials of approved RSV vaccines.
To examine prominent platform technologies in RSV vaccine research.
To discuss combination vaccines targeting RSV, HMPV, and Human Parainfluenza Virus Type 3 (HPIV3).

Main Methods:

Analysis of clinical trial data for approved RSV vaccines.
Review of emerging RSV vaccine platform technologies.
Discussion of combination vaccine candidates in clinical development.

Main Results:

Three RSV vaccines (AREXVY®, ABRYSVO®, mRESVIA®) have been approved, primarily for older adults.
ABRYSVO® offers passive immunization for infants through maternal vaccination.
RSV vaccine technologies and combination vaccines are under active clinical evaluation.

Conclusions:

Significant advancements have been achieved in RSV vaccine development with multiple approved options.
Vaccines for HMPV remain a critical unmet medical need.
Combination vaccines represent a promising strategy for broad protection against multiple respiratory viruses.